Literature DB >> 28094184

In vivo evaluation of IGF1R/IR PET ligand [18F]BMS-754807 in rodents.

Jaya Prabhakaran1, Stephen L Dewey2, Richard McClure3, Norman R Simpson4, Mohammed N Tantawy5, J John Mann1, Wellington Pham3, J S Dileep Kumar6.   

Abstract

In vivo evaluation of [18F]BMS-754807 binding in mice and rats using microPET and biodistribution methods is described herein. The radioligand shows consistent binding characteristics, in vivo, in both species. Early time frames of the microPET images and time activity curves of brain indicate poor penetration of the tracer across the blood brain barrier (BBB) in both species. However, microPET experiments in mice and rats show high binding of the radioligand outside the brain to heart, pancreas and muscle, the organs known for higher expression of IGF1R/1R. Biodistribution analysis 2h after injection of [18F]BMS-754807 in rats show negligible [18F]defluorination as reflected by the low bone uptake and clearance from blood. Overall, the data indicate that [18F]BMS-754807 can potentially be a radiotracer for the quantification of IGF1R/IR outside the brain using PET.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  IGF1R; IR; Insulin; MicroPET; Radiotracer

Mesh:

Substances:

Year:  2017        PMID: 28094184      PMCID: PMC5846678          DOI: 10.1016/j.bmcl.2016.12.086

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  26 in total

Review 1.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

Authors:  Robert G Maki
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

Review 2.  Regulation and physiological role of insulin-like growth factor binding proteins.

Authors:  C A Conover
Journal:  Endocr J       Date:  1996-10       Impact factor: 2.349

3.  Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.

Authors:  Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Addy C M van de Luijtgaarden; Janneke D M Molkenboer-Kuenen; Sandra Heskamp; Melissa H S Roeffen; Hanneke W M van Laarhoven; Peter J Houghton; Wim J G Oyen; Otto C Boerman; Winette T A van der Graaf
Journal:  Clin Cancer Res       Date:  2011-10-28       Impact factor: 12.531

4.  BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

Authors:  Joan M Carboni; Mark Wittman; Zheng Yang; Francis Lee; Ann Greer; Warren Hurlburt; Stephen Hillerman; Carolyn Cao; Glenn H Cantor; Janet Dell-John; Cliff Chen; Lorell Discenza; Krista Menard; Aixin Li; George Trainor; Dolatrai Vyas; Robert Kramer; Ricardo M Attar; Marco M Gottardis
Journal:  Mol Cancer Ther       Date:  2009-12       Impact factor: 6.261

Review 5.  Insulin-like growth factor: current concepts and new developments in cancer therapy.

Authors:  Erin R King; Kwong-Kwok Wong
Journal:  Recent Pat Anticancer Drug Discov       Date:  2012-01       Impact factor: 4.169

Review 6.  Insulin-like growth factor receptor inhibitors: baby or the bathwater?

Authors:  Douglas Yee
Journal:  J Natl Cancer Inst       Date:  2012-07-03       Impact factor: 13.506

7.  Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551.

Authors:  Vladimir Tolmachev; Jennie Malmberg; Camilla Hofström; Lars Abrahmsén; Thomas Bergman; Anna Sjöberg; Mattias Sandström; Torbjörn Gräslund; Anna Orlova
Journal:  J Nucl Med       Date:  2011-12-15       Impact factor: 10.057

Review 8.  Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.

Authors:  A Gualberto; M Pollak
Journal:  Oncogene       Date:  2009-07-06       Impact factor: 9.867

9.  A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.

Authors:  Kyle G Halvorson; Kelly L Barton; Kristin Schroeder; Katherine L Misuraca; Christine Hoeman; Alex Chung; Donna M Crabtree; Francisco J Cordero; Raj Singh; Ivan Spasojevic; Noah Berlow; Ranadip Pal; Oren J Becher
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

10.  Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore.

Authors:  H Zhang; X Zeng; Q Li; M Gaillard-Kelly; C R Wagner; D Yee
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

View more
  3 in total

Review 1.  Molecular Imaging of IGF-1R in Cancer.

Authors:  Yingying Sun; Xilin Sun; Baozhong Shen
Journal:  Mol Imaging       Date:  2017 Jan-Dec       Impact factor: 4.488

2.  Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT.

Authors:  Yongsheng Liu; Shengze Yu; Tianqi Xu; Vitalina Bodenko; Anna Orlova; Maryam Oroujeni; Sara S Rinne; Vladimir Tolmachev; Anzhelika Vorobyeva; Torbjörn Gräslund
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

Review 3.  Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.

Authors:  Julie Bolcaen; Shankari Nair; Cathryn H S Driver; Tebatso M G Boshomane; Thomas Ebenhan; Charlot Vandevoorde
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.